Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.
2.

Single-Vector, Single-Injection Recombinant Vesicular Stomatitis Virus Vaccines Against High-Containment Viruses.

Whitt MA, Geisbert TW, Mire CE.

Methods Mol Biol. 2016;1403:295-311. doi: 10.1007/978-1-4939-3387-7_16.

PMID:
27076138
3.

Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.

Chang G, Xu S, Watanabe M, Jayakar HR, Whitt MA, Gingrich JR.

J Urol. 2010 Apr;183(4):1611-8. doi: 10.1016/j.juro.2009.12.005. Epub 2010 Feb 20.

PMID:
20172545
4.

Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.

Chattopadhyay A, Rose JK.

J Virol. 2011 Mar;85(5):2004-11. doi: 10.1128/JVI.01852-10. Epub 2010 Dec 22.

6.

Leucine-rich repeat-containing G protein-coupled receptor 4 facilitates vesicular stomatitis virus infection by binding vesicular stomatitis virus glycoprotein.

Zhang N, Huang H, Tan B, Wei Y, Xiong Q, Yan Y, Hou L, Wu N, Siwko S, Cimarelli A, Xu J, Han H, Qian M, Liu M, Du B.

J Biol Chem. 2017 Oct 6;292(40):16527-16538. doi: 10.1074/jbc.M117.802090. Epub 2017 Aug 23.

PMID:
28842478
7.

Use of influenza C virus glycoprotein HEF for generation of vesicular stomatitis virus pseudotypes.

Hanika A, Larisch B, Steinmann E, Schwegmann-Wessels C, Herrler G, Zimmer G.

J Gen Virol. 2005 May;86(Pt 5):1455-65.

PMID:
15831958
8.

Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector.

Ma Y, Duan Y, Wei Y, Liang X, Niewiesk S, Oglesbee M, Li J.

J Virol. 2014 May;88(9):5122-37. doi: 10.1128/JVI.00019-14. Epub 2014 Feb 26.

9.

Formation of bovine viral diarrhea virus E1-E2 heterodimers is essential for virus entry and depends on charged residues in the transmembrane domains.

Ronecker S, Zimmer G, Herrler G, Greiser-Wilke I, Grummer B.

J Gen Virol. 2008 Sep;89(Pt 9):2114-21. doi: 10.1099/vir.0.2008/001792-0.

PMID:
18753220
10.

Spontaneous Mutation at Amino Acid 544 of the Ebola Virus Glycoprotein Potentiates Virus Entry and Selection in Tissue Culture.

Ruedas JB, Ladner JT, Ettinger CR, Gummuluru S, Palacios G, Connor JH.

J Virol. 2017 Jul 12;91(15). pii: e00392-17. doi: 10.1128/JVI.00392-17. Print 2017 Aug 1.

PMID:
28539437
11.

Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus.

Matassov D, Marzi A, Latham T, Xu R, Ota-Setlik A, Feldmann F, Geisbert JB, Mire CE, Hamm S, Nowak B, Egan MA, Geisbert TW, Eldridge JH, Feldmann H, Clarke DK.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S443-51. doi: 10.1093/infdis/jiv316. Epub 2015 Jun 24.

12.

Evaluation of attenuated VSVs with mutated M or/and G proteins as vaccine vectors.

Fang X, Zhang S, Sun X, Li J, Sun T.

Vaccine. 2012 Feb 8;30(7):1313-21. doi: 10.1016/j.vaccine.2011.12.085. Epub 2012 Jan 2.

PMID:
22222871
14.

The stem of vesicular stomatitis virus G can be replaced with the HIV-1 Env membrane-proximal external region without loss of G function or membrane-proximal external region antigenic properties.

Lorenz IC, Nguyen HT, Kemelman M, Lindsay RW, Yuan M, Wright KJ, Arendt H, Back JW, DeStefano J, Hoffenberg S, Morrow G, Jurgens CK, Phogat SK, Zamb TJ, Parks CL.

AIDS Res Hum Retroviruses. 2014 Nov;30(11):1130-44. doi: 10.1089/AID.2013.0206. Epub 2014 Apr 9.

15.

High-throughput screening of viral entry inhibitors using pseudotyped virus.

Basu A, Mills DM, Bowlin TL.

Curr Protoc Pharmacol. 2010 Dec;Chapter 13:Unit 13B.3. doi: 10.1002/0471141755.ph13b03s51.

PMID:
21935898
16.

Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice.

Cooper D, Wright KJ, Calderon PC, Guo M, Nasar F, Johnson JE, Coleman JW, Lee M, Kotash C, Yurgelonis I, Natuk RJ, Hendry RM, Udem SA, Clarke DK.

J Virol. 2008 Jan;82(1):207-19. Epub 2007 Oct 17.

17.

Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates.

Mire CE, Miller AD, Carville A, Westmoreland SV, Geisbert JB, Mansfield KG, Feldmann H, Hensley LE, Geisbert TW.

PLoS Negl Trop Dis. 2012;6(3):e1567. doi: 10.1371/journal.pntd.0001567. Epub 2012 Mar 20.

18.

Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.

Sung CK, Choi B, Wanna G, Genden EM, Woo SL, Shin EJ.

Laryngoscope. 2008 Feb;118(2):237-42.

PMID:
18043494
19.

Characterization of the Bas-Congo virus glycoprotein and its function in pseudotyped viruses.

Steffen I, Liss NM, Schneider BS, Fair JN, Chiu CY, Simmons G.

J Virol. 2013 Sep;87(17):9558-68. doi: 10.1128/JVI.01183-13. Epub 2013 Jun 19.

20.

Supplemental Content

Support Center